3//SEC Filing
Merck KGaA 3
Accession 0001104659-21-128645
CIK 0001840233other
Filed
Oct 20, 8:00 PM ET
Accepted
Oct 21, 8:50 PM ET
Size
6.6 KB
Accession
0001104659-21-128645
Insider Transaction Report
Form 3
Merck KGaA
10% Owner
Holdings
- (indirect: See footnote)
Series C Preferred Stock
→ Common Stock (264,765 underlying) - (indirect: See footnote)
Series B Preferred Stock
→ Common Stock (416,060 underlying)
Footnotes (3)
- [F1]The Series B Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- [F2]The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V.
- [F3]The Series C Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
Documents
Issuer
Xilio Therapeutics, Inc.
CIK 0001840233
Entity typeother
IncorporatedGermany
Related Parties
1- filerCIK 0001764133
Filing Metadata
- Form type
- 3
- Filed
- Oct 20, 8:00 PM ET
- Accepted
- Oct 21, 8:50 PM ET
- Size
- 6.6 KB